Director/PDMR Shareholding

Phytopharm PLC
10 November 2006

NOTIFICATION OF TRANSACTIONS OF DIRECTORS, 
PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY OR CONNECTED PERSONS


This form is intended for use by an issuer to make a RIS notification required
by DR 3.1.4R(1).

(1)     An issuer making a notification in respect of a transaction 
        relating to the shares or debentures of the issuer should complete
        boxes 1 to 16, 23 and 24.
(2)     An issuer making a notification in respect of a derivative relating 
        to the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 
        16, 23 and 24. 
(3)     An issuer making a notification in respect of options granted to a 
        director/person discharging managerial responsibilities should 
        complete boxes 1 to 3 and 17 to 24. 
(4)     An issuer making a notification in respect of a financial 
        instrument relating to the shares of the issuer (other than a 
        debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 
        23 and 24. 


Please complete all relevant boxes in block capital letters.


1.   Name of the issuer   
           
     PHYTOPHARM PLC


2.   State whether the notification relates to (i) a transaction 
     notified in accordance with DR 3.1.4R(1)(a); or

     (ii) DR 3.1.4(R)(1)(b) a disclosure made in accordance with section 324 
     (as extended by section 328) of the Companies Act 1985; or 

     (iii) both (i) and (ii)

     NOTIFICATION RELATES TO (iii)

               
3.   Name of person discharging managerial responsibilities/director  

     DR DARYL REES

        
4.   State whether notification relates to a person connected with a person
     discharging managerial responsibilities/director named in 3 and identify 
     the connected person
 
     AS 3 ABOVE

        
5.   Indicate whether the notification is in respect of a holding of the person 
     referred to in 3 or 4 above or in respect of a non-beneficial interest      




6.   Description of shares (including class), debentures or derivatives or 
     financial instruments relating to shares



               
7.   Name of registered shareholders(s) and, if more than one, the number of
     shares held by each of them   




8.   State the nature of the transaction
               



9.   Number of shares, debentures or financial instruments relating to shares 
     acquired 




10.  Percentage of issued class acquired (treasury shares of that class should 
     not be taken into account when calculating percentage)



               
11.  Number of shares, debentures or financial instruments relating to shares
     disposed     




12.  Percentage of issued class disposed (treasury shares of that class should
     not be taken into account when calculating percentage) 



               
13.  Price per share or value of transaction    




14.  Date and place of transaction


               

15.  Total holding following notification and total percentage holding following 
     notification (any treasury shares should not be taken into account when 
     calculating percentage)   




16.  Date issuer informed of transaction


               

If a person discharging managerial responsibilities has been granted options by 
the issuer complete the following boxes




17.  Date of grant   

     8 NOVEMBER 2006


18.  Period during which or date on which it can be exercised

     8 NOVEMBER 2009 TO 7 NOVEMBER 2016

               
19.  Total amount paid (if any) for grant of the option  

     NIL


20.  Description of shares or debentures involved (class and number)

     52,724 PHYTOPHARM PLC ORDINARY 1 PENCE SHARES

               
21.  Exercise price (if fixed at time of grant) or indication that price is 
     to be fixed at the time of exercise     

     FORTY SIX AND THREE QUARTER PENCE


22.  Total number of shares or debentures over which options held following 
     notification
               
     858,974


23.  Any additional information  

     PERFORMANCE CRITERIA ARE BASED ON TOTAL SHAREHOLDER RETURN COMPARED TO
     COMPARATOR GROUPS ON THE THIRD ANNIVERSARY OF GRANT. NO OPTIONS VEST FOR
     BELOW MEDIAN PERFORMANCE AND 100% VEST FOR UPPER QUARTILE PERFORMANCE AND 
     ABOVE WITH PRO RATA VESTING BETWEEN MEDIAN AND UPPER QUARTILE PERFORMANCE.
     FOR 26,362 OPTIONS THE COMPARATOR GROUP COMPRISES 25 OTHER UK LISTED 
     BIOTECH COMPANIES AND FOR 26,362 OPTIONS THE COMPARATOR GROUP IS THE FTSE
     SMALL CAP INDEX.


24.  Name of contact and telephone number for queries

     ZOE MCGOWAN
     01480 437697
               

Name and signature of duly authorised officer of issuer responsible for 
making notification

     ZOE MCGOWAN


Date of notification      10 NOVEMBER 2006




                      This information is provided by RNS
            The company news service from the London Stock Exchange